论文部分内容阅读
将急性心肌梗塞（ＡＭＩ）蝮蛇抗栓酶静脉治疗组（ＶＡＥ组）５１例与大剂量尿激酶静脉治疗组（ＵＫ组）３８例相比较，冠脉再通率分别为３９．２２％（２Ｚ／５１）与６０．５３％（２３／３８）（Ｐ＜０．０１）；５周病死率分别为９．８０％（５／５１）与７．８９％（３／３８）（Ｐ＜０．０１）；出血率分别为１３．７２％（７／５１）与１３．１６％（５／３８）（Ｐ＞０．０５）；ＱＲＳ记分分别为３．１２±０．４２与２．７９±０．３９（０．０５＞Ｐ＞０．０１）；ＣＫ峰值分别为２４８．７３±３１．２２Ｕ与２１９．６８±２３．１６Ｕ（０．０５＞Ｐ＞０．０１）。显然，ＵＫ组疗效明显优于ＶＡＥ组。推荐ＵＫ的适宜用量为１５０万Ｕ３０分钟内静脉滴入。
51 cases of acute myocardial infarction (AMI) viper antithrombotic venous treatment group (VAE group) and 38 cases of high dose urokinase vein treatment group (UK group) compared to coronary recanalization rates were 39.22% ( 2Z / 51) and 60.53% (23/38) respectively (P <0.01). The 5-week mortality rates were 9.80% (5/51) and 7.89% 0.01). The hemorrhage rates were 13.72% (7/51) and 13.16% (5/38) respectively (P> 0.05). The QRS scores were 3.12 ± 0.42 and 2 respectively. 79 ± 0.39 (0.05> P> 0.01). The peak values of CK were 248.73 ± 31.22U and 219.68 ± 23.16U (0.05> P> 0.01), respectively. Obviously, the UK group was significantly better than the VAE group. Recommended the appropriate amount of UK 1.5 million U30 intravenous infusion within 30 minutes.